RESEARCH USING PATIENTS WHO FIT THE INTERNATIONAL CONSENSUS CRITERIA*
Please share this page to your favorite social media sites!
Skewing of the B cell receptor repertoire in ME/CFS Sato, Ono, Matsutani, Nakamura, Shin, Amano, Suzuki & Yamamura (Japan) - ICC, CCC and Fukuda - Conclusion: "... we revealed a biased usage of several IGHV genes in peripheral blood B cells from ME/CFS patients. Results of receiver operating characteristic (ROC) analysis further indicated a possibility of distinguishing patients from healthy controls, based on the skewed B cell repertoire." - 27 March 21
Open-label study with the monoamine stabilizer (-)-OSU6162 in ME/CFS Haghighi, Forsmark, Zachrisson, Carlsson, Nilsson, Carlsson, Schuit & Gottfries (Sweden & The Netherlands) - ICC and Fukuda - Conclusion: "(‐)‐OSU6162 is well tolerated in ME/CFS patients and shows promise as a novel treatment to mitigate fatigue and improve mood and health‐related quality of life in ME/CFS. Obviously, the present results need to be confirmed in future placebo‐controlled double‐blind trials." - 02 February 21
The Economic Impacts of ME/CFS in an Australian Cohort Close, Marshall-Gradisnik, Byrnes, Smith, Nghiem and Stains (Australia) - Conclusion: The economic impacts of ME/CFS in Australia are significant. Improved understanding of the illness pathology, diagnosis, and management, may reduce costs, improve patient prognosis and decrease the burden of ME/CFS in Australia. - 21 August 20
Review of case definitions for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Lim and Son (Republic of Korea) - "...ME/CFS has been named differently (e.g., postviral fatigue syndrome, neurasthenia) depending on the perspectives of the researchers; likewise, diagnostic criteria or case definitions have also been changed accordingly." Conclusions: "In this review, we found three key factors that have affected ME/CFS case definitions: etiology, pathophysiology, and exclusionary disorders. These factors have impacted the specification of the main symptoms, required conditions, and range of inclusive and exclusive symptoms/disorders in the development of case definitions." - 29 July 20
Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with CFS Loebel, Grabowski, Heidecke, Bauer, Hanitsch, Wittke, Meisel, Reinke, Volk, Fluge, Mella and Scheibenbogen (Germany & Norway) Results: "We found significantly higher autoantibody levels against M3 and M4 AChR and β2 AdR in CFS patients compared to controls. Crossreactivity between all 5 M and β1 and β2 AdR but also between M and β receptor was seen in a substantial portion of CFS patients as shown for M4 in Fig. 1C. The highest correlation was found between M3 and M4 receptor antibodies (r = 0.87), the lowest for M1 and M4 receptor antibodies (r = 0.59)." - 19 Sept 15
Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in ME/CFS Patient selection - CCC Schreiner, Harrer, Scheibenbogen, Lamer, Schlosser, Naviaux and Prusty (Germany/US) - 01 April 20
Note: Some studies use various labels (ME/CFS, CFS, CFS/ME) due to the inconsistent use of these labels worldwide. This list focuses on the research subjects used showing research is applicable to myalgic encephalomyelitis.
The information provided at this site is not intended to diagnose or treat any illness and is not to be considered as medical advice. ME International is a 501(c)(3) nonprofit and is listed as a nonprofit corporation with the state of Colorado.
copyright 2019-2021 ME International EIN 84-3568066